Els Japan Solutions

Els Japan Solutions company information, Employees & Contact Information

Eliquent Japan, formerly known as IDEC, is a Japanese regulatory consulting company. We provide comprehensive regulatory services, market assessment service, licensing support service, etc. We are a part of ELIQUENT Life Sciences that creates an unprecedented assembly of global regulatory leaders, industry experts, and technical specialists - brought together to bridge the spectrum of regulatory challenges across the product lifecycle. The collective capabilities of the united ELIQUENT team enable a comprehensive approach that delivers integrated solutions to support pharmaceutical, biotechnology, medical device, and combination product companies navigating the complex global regulatory landscape. From thought to finish, concept to commerce, and strategy to execution— ELIQUENT Life Sciences is the singular regulatory resource that clients around the world trust. LEARN MORE about our strategic repositioning and integrated service offerings at eliquent.com Recently, we have created GPTs, “Japan Regulatory Insight,” that allow Q&A about newly issued regulatory notifications in Japan regarding the Japanese Phase 1 waiver and orphan drug designation, which have attracted much attention. If you are a ChatGPT Plus subscriber, please click the link below to use the GPTs "Japan Regulatory Insight." https://chat.openai.com/g/g-D5L83iRSi-japan-regulatory-insight If you would like more detailed advice on your project than GPTs's general advice, please get in touch with Eliquent Japan!

Company Details

Employees
18
Founded
-
Address
Shinjuku, Tokyo 1631341, Jp
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Shinjuku, Tokyo
Looking for a particular Els Japan Solutions employee's phone or email?

Els Japan Solutions Questions

News

Biogen Idec Increases Revenue 7% to $1.3 Billion in the First Quarter - Biogen

Biogen Idec Increases Revenue 7% to $1.3 Billion in the First Quarter Biogen

Biogen Drops Idec From Name - The Wall Street Journal

Biogen Drops Idec From Name The Wall Street Journal

Biogen Idec Inc. (BIIB) Has Risen To Another New High - RTTNews

Biogen Idec Inc. (BIIB) Has Risen To Another New High RTTNews

Biogen Idec Announces Collaboration with Leading Research Institutions to Sequence Genomes of Patients with ALS - Biogen

Biogen Idec Announces Collaboration with Leading Research Institutions to Sequence Genomes of Patients with ALS Biogen

Biogen Idec Inc. (BIIB) Is Sinking Following Q3 Report - RTTNews

Biogen Idec Inc. (BIIB) Is Sinking Following Q3 Report RTTNews

Biogen Idec Prices $1.0 Billion Senior Unsecured Notes Offering - Biogen

Biogen Idec Prices $1.0 Billion Senior Unsecured Notes Offering Biogen

Biogen Idec Inc. (BIIB) Has Fallen Below Today's Range - RTTNews

Biogen Idec Inc. (BIIB) Has Fallen Below Today's Range RTTNews

Biogen Idec First Quarter 2014 Revenues Reach $2.1 Billion Driven by Continued Strength of MS Franchise - Biogen

Biogen Idec First Quarter 2014 Revenues Reach $2.1 Billion Driven by Continued Strength of MS Franchise Biogen

Biogen Idec Inc. (BIIB) Is Heading Higher Following Q4 Report - RTTNews

Biogen Idec Inc. (BIIB) Is Heading Higher Following Q4 Report RTTNews

Biogen Idec Names Brian S. Posner to Board of Directors - Biogen

Biogen Idec Names Brian S. Posner to Board of Directors Biogen

Biogen Idec Inc. (BIIB) Has Set A New High For The Year - RTTNews

Biogen Idec Inc. (BIIB) Has Set A New High For The Year RTTNews

Biogen Idec Inc. (BIIB) Is Rising On Study Results - RTTNews

Biogen Idec Inc. (BIIB) Is Rising On Study Results RTTNews

Biogen Idec Celebrates 30 Years of Transforming Discovery into Care - Biogen

Biogen Idec Celebrates 30 Years of Transforming Discovery into Care Biogen

Biogen Idec Inc. (BIIB) Has Risen Past Resistance At The Highs - RTTNews

Biogen Idec Inc. (BIIB) Has Risen Past Resistance At The Highs RTTNews

Biogen Idec Inc. Rose To Another New High For The Year - RTTNews

Biogen Idec Inc. Rose To Another New High For The Year RTTNews

Biogen Idec Inc. (BIIB) Climbed Past Resistance At The Highs - RTTNews

Biogen Idec Inc. (BIIB) Climbed Past Resistance At The Highs RTTNews

Biogen Idec Inc. (BIIB) Rose To A New High For The Year - RTTNews

Biogen Idec Inc. (BIIB) Rose To A New High For The Year RTTNews

Biogen Idec Inc. (BIIB) Fell To A 6-Week Low After Downgrade - RTTNews

Biogen Idec Inc. (BIIB) Fell To A 6-Week Low After Downgrade RTTNews

Biogen Idec Inc. Finished At A New High For The Year - RTTNews

Biogen Idec Inc. Finished At A New High For The Year RTTNews

Biogen Idec Inc. (BIIB) Is Climbing After Q4 Earnings Topped Expectations - RTTNews

Biogen Idec Inc. (BIIB) Is Climbing After Q4 Earnings Topped Expectations RTTNews

Biogen Idec Inc. (BIIB) Is Trading At A New High For The Year - RTTNews

Biogen Idec Inc. (BIIB) Is Trading At A New High For The Year RTTNews

Biogen Idec Inc. (BIIB) Has Climbed Past Resistance At The Highs - RTTNews

Biogen Idec Inc. (BIIB) Has Climbed Past Resistance At The Highs RTTNews

Biogen Idec Inc. (BIIB) Has Surged To A New High After Acquiring TYSABRI - RTTNews

Biogen Idec Inc. (BIIB) Has Surged To A New High After Acquiring TYSABRI RTTNews

Biogen Idec Inc. Added To Recent Gains - RTTNews

Biogen Idec Inc. Added To Recent Gains RTTNews

Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion - Biogen

Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion Biogen

Biogen Idec Inc. (BIIB) Has Risen To A New High After FDA Approval - RTTNews

Biogen Idec Inc. (BIIB) Has Risen To A New High After FDA Approval RTTNews

Biogen Idec Inc. Has Slipped Below Today's Range - RTTNews

Biogen Idec Inc. Has Slipped Below Today's Range RTTNews

Biogen Idec Inc. (BIIB) Rose To A New High For The Year - RTTNews

Biogen Idec Inc. (BIIB) Rose To A New High For The Year RTTNews

Biogen Idec Inc. Is Trading At Over A 7-Month High - RTTNews

Biogen Idec Inc. Is Trading At Over A 7-Month High RTTNews

Biogen Idec Announces Framework for Growth Through Increased Focus and Efficiency - Biogen

Biogen Idec Announces Framework for Growth Through Increased Focus and Efficiency Biogen

Biogen Idec Inc. Climbed Above A Trading Range At The Highs - RTTNews

Biogen Idec Inc. Climbed Above A Trading Range At The Highs RTTNews

Biogen Idec Inc. Has Re-Crossed Its 200-Day Moving Average - RTTNews

Biogen Idec Inc. Has Re-Crossed Its 200-Day Moving Average RTTNews

Biogen Idec Inc. Has Re-Crossed Its 50-Day Moving Average - RTTNews

Biogen Idec Inc. Has Re-Crossed Its 50-Day Moving Average RTTNews

Biogen Idec Inc. Has Re-Crossed Its 200-Day Moving Average - RTTNews

Biogen Idec Inc. Has Re-Crossed Its 200-Day Moving Average RTTNews

Biogen Idec Inc. (BIIB) Surged To A New High On TECFIDERA Exclusivity News - RTTNews

Biogen Idec Inc. (BIIB) Surged To A New High On TECFIDERA Exclusivity News RTTNews

Biogen Idec Q4 Profit Up - Quick Facts - RTTNews

Biogen Idec Q4 Profit Up - Quick Facts RTTNews

Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech - Biogen

Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech Biogen

Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis - Biogen

Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis Biogen

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Myotonic Dystrophy - Biogen

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Myotonic Dystrophy Biogen

Biogen Idec Q1 Profit Declines - Quick Facts - RTTNews

Biogen Idec Q1 Profit Declines - Quick Facts RTTNews

Biogen Idec Inc. (BIIB): The Short Data You Need To See - Insider Monkey

Biogen Idec Inc. (BIIB): The Short Data You Need To See Insider Monkey

Biogen Idec To Present At Cowen And Company Conference; Webcast At 2:50 PM ET - RTTNews

Biogen Idec To Present At Cowen And Company Conference; Webcast At 2:50 PM ET RTTNews

Biogen Idec Q1 Profit Declines; Announces $1.5 Bln Share Buyback - Quick Facts 2 - RTTNews

Biogen Idec Q1 Profit Declines; Announces $1.5 Bln Share Buyback - Quick Facts 2 RTTNews

Biogen Idec Names George Scangos Chief Executive Officer - Update - RTTNews

Biogen Idec Names George Scangos Chief Executive Officer - Update RTTNews

Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for Upfront Cash and Contingent Payments - Biogen

Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for Upfront Cash and Contingent Payments Biogen

Glowing Tysabri Sales Data Fails To Lift Biogen Idec - RTTNews

Glowing Tysabri Sales Data Fails To Lift Biogen Idec RTTNews

Icahn revives proxy fight with Biogen Idec; seeks shareholder support in proxy filing - RTTNews

Icahn revives proxy fight with Biogen Idec; seeks shareholder support in proxy filing RTTNews

IDEC Corp. Develops New HT4P Safety Commander - FoodEngineeringMag.com

IDEC Corp. Develops New HT4P Safety Commander FoodEngineeringMag.com

Biogen Idec to Acquire Stromedix - Biogen

Biogen Idec to Acquire Stromedix Biogen

DC Advisory advised IDEC Corporation on the acquisition of Apem Group from ICG - DC Advisory

DC Advisory advised IDEC Corporation on the acquisition of Apem Group from ICG DC Advisory

IDEC Corporation Introduces Compact Combined PLC+HMI - FoodEngineeringMag.com

IDEC Corporation Introduces Compact Combined PLC+HMI FoodEngineeringMag.com

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant